BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Cipla
Federal Trade Commission
Queensland Health
US Army
Baxter
Colorcon
US Department of Justice
Chinese Patent Office
Boehringer Ingelheim

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,332,481

« Back to Dashboard

Which drugs does patent 7,332,481 protect, and when does it expire?

Patent 7,332,481 protects PROMACTA and is included in two NDAs.

Protection for PROMACTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-three patent family members in twenty-eight countries.
Summary for Patent: 7,332,481
Title:Thrombopoietin mimetics
Abstract:Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s): Duffy; Kevin J. (Collegeville, PA), Erickson-Miller; Connie (Collegeville, PA), Jenkins; Julian (Collegeville, PA), Luengo; Juan (Collegeville, PA), Price; Alan T. (Collegeville, PA), Shaw; Antony N. (Collegeville, PA), Visonneau; Sophie (San Diego, PA), Wiggall; Kenneth (Collegeville, PA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:11/620,260
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,332,481

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp PROMACTA eltrombopag olamine FOR SUSPENSION;ORAL 207027-001 Aug 24, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-004 Oct 20, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-001 Nov 20, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-002 Nov 20, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-003 Sep 8, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-005 Nov 16, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,332,481

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,473,686 Thrombopoietin mimetics ➤ Subscribe
7,160,870 Thrombopoietin mimetics ➤ Subscribe
7,790,704 Thrombopoietin mimetics ➤ Subscribe
7,335,649 Thrombopoietin mimetics ➤ Subscribe
7,648,971 Thrombopoietin mimetics ➤ Subscribe
7,452,874 Thrombopoietin mimetics ➤ Subscribe
7,439,342 Thrombopoietin mimetics ➤ Subscribe
7,674,887 Thrombopoietin mimetics ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,332,481

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 030696 ➤ Subscribe
Argentina 066036 ➤ Subscribe
Austria 374772 ➤ Subscribe
Austria 445606 ➤ Subscribe
Australia 2001274938 ➤ Subscribe
Australia 7493801 ➤ Subscribe
Brazil 0111116 ➤ Subscribe
Canada 2411468 ➤ Subscribe
China 100423721 ➤ Subscribe
China 101342169 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Boehringer Ingelheim
Colorcon
Mallinckrodt
Julphar
Farmers Insurance
Citi
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot